Little Rock, Arkansas 72205

  • Squamous Cell Carcinoma of the Head and Neck


This is a research study to evaluate the quality of life and amount of dry mouth experienced as a result of radiotherapy in subjects who have squamous cell carcinoma of the head and neck (HN-SQCC). This study will compare the side effects experienced based on the method to plan radiotherapy, Margin Based or Robust.

Study summary:

This is a prospective randomized pilot clinical trial, stratified by primary tumor site, to evaluate the degree of xerostomia and quality of life (QOL) in subjects with HN-SQCC treated with radiation therapy under margin-based and robust radiotherapy treatment plans. Margin-based plans will use both biological (biological optimization) and physical objectives whereas robust planning will use physical objectives for sparing of the parotid glands. Intensity-modulated radiation therapy (IMRT) and standard chemotherapy will be used. QOL (quality of life) will be measured using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 questionnaire and EORTC QLQ-H&N35 (head and neck) module before radiotherapy (baseline) and then 3, 6, 9 and 12 months after radiotherapy. Xerostomia will be measured in study subjects using two patient-reported scoring systems completed by each subject before radiotherapy and then 3, 6, 9, and 12 months after radiotherapy: Late Effects Normal Tissue Task Force (LENT)-Subjective, Objective, Management, Analytic (SOMA) LENT/SOMA grading system and the University of Michigan's Xerostomia Questionnaire (XQ). The data collected by this randomized pilot clinical trial will be used to inform the design of, and decision-making for, future larger studies that seek to compare different methods of radiotherapy planning in the treatment of HN-SQCC.


Inclusion Criteria: - Histological documentation of Squamous-Cell Carcinoma of the Head and Neck (HN-SQCC) - Older than 21 years of age - Subject is eligible for routine chemo-radiotherapy for treatment of HN-SQCC - Informed consent is obtained - Karnofsky performance of at least 70 points Exclusion Criteria: - Women with a positive urine pregnancy test are excluded from this study; women of childbearing potential must agree to refrain from breast feeding and practice adequate contraception - Unable to comply with study procedures - Use of saliva stimulating prescription drugs such as Evoxac or Salagen - Unable to receive standard chemotherapy



Primary Contact:

Principal Investigator
Thomas Kim, MD
University of Arkansas

Backup Contact:


Location Contact:

Little Rock, Arkansas 72205
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 13, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.